Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Terumo Ends Boston Scientific Deal to Start Urology Unit

Feb. 19 (Bloomberg) -- Terumo Corp., Asia’s biggest maker of medical devices, plans to end a urology partnership with Boston Scientific Corp. in the U.S. and create its own sales, marketing and distribution unit for the products in April.

Creating the urology unit will provide better access to a U.S. market estimated to generate $2.3 billion in sales by 2016, the Tokyo-based company said in a statement today. The Terumo Interventional Systems unit sells devices including guidewires and catheters that give doctors access to the heart and peripheral blood vessels to treat disease.

Terumo ended a similar relationship with Natick, Massachusetts-based Boston Scientific for heart devices in 2006. Terumo’s Glidewire products are used in one-third of minimally invasive urological procedures each year in the U.S., such as the treatment of kidney stones. About 685,000 Americans annually are treated for kidney stones, the accumulation of hard and painful crystals inside the kidneys.

“We are committed to meeting the growing demands of this important customer base,” said James Rushworth, president of Terumo Interventional Systems and the Onset Medical unit that the company purchased in January 2012 for its sheath technology. “Terumo Interventional Systems plans to introduce a steady stream of devices inspired by clinical performance, economic advantages, and improved quality of life for patients.”

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.